283 related articles for article (PubMed ID: 9826477)
1. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
Monk BJ; Alberts DS; Burger RA; Fanta PT; Hallum AV; Hatch KD; Salmon SE
Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477
[TBL] [Abstract][Full Text] [Related]
2. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
3. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin.
Koshiyama M; Kinezaki M; Uchida T; Sumitomo M
Anticancer Res; 2005; 25(6C):4499-502. PubMed ID: 16334133
[TBL] [Abstract][Full Text] [Related]
5. Activity of oxaliplatin against human tumor colony-forming units.
Raymond E; Lawrence R; Izbicka E; Faivre S; Von Hoff DD
Clin Cancer Res; 1998 Apr; 4(4):1021-9. PubMed ID: 9563898
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF
Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322
[TBL] [Abstract][Full Text] [Related]
7. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand.
Koivusalo R; Krausz E; Ruotsalainen P; Helenius H; Hietanen S
Cancer Res; 2002 Dec; 62(24):7364-71. PubMed ID: 12499281
[TBL] [Abstract][Full Text] [Related]
8. [Phase I study of a combination chemotherapy of nedaplatin and cisplatin].
Nishida M; Satoh Y; Nishide K; Tsunoda H; Kubo T
Gan To Kagaku Ryoho; 1999 Dec; 26(14):2209-15. PubMed ID: 10635306
[TBL] [Abstract][Full Text] [Related]
9. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
10. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a new platinum compound (glycolate-o,o') diammineplatinum (II) (254-S), against non-small cell lung carcinoma grown in a human tumor clonogenic assay system.
Kanzawa F; Matsushima Y; Nakano H; Nakagawa K; Takahashi H; Sasaki Y; Saijo N
Anticancer Res; 1988; 8(3):323-7. PubMed ID: 2839098
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
13. Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical cancer.
Adachi S; Ogasawara T; Tsubamoto H; Oku H; Hori Y; Tsuji Y; Takemura T; Koyama K
Int J Clin Pharmacol Res; 2001; 21(3-4):105-10. PubMed ID: 12067139
[TBL] [Abstract][Full Text] [Related]
14. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of cisplatin and cisdiammine-1,1-cyclobutane dicarboxylate in MGH-U1 cells grown as monolayers, spheroids, and xenografts.
Erlichman C; Vidgen D; Wu A
J Natl Cancer Inst; 1985 Sep; 75(3):499-505. PubMed ID: 3897683
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
17. Platinum compounds in cervical and endometrial cancers: focus on carboplatin.
Muggia FM; Muderspach L
Semin Oncol; 1994 Apr; 21(2 Suppl 2):35-41; quiz 42, 58. PubMed ID: 8202719
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of new combination chemotherapy with irinotecan hydrochloride and nedaplatin against human cervical cancer cell lines.
Yamamoto K; Iwahana M; Kumazawa E; Kakihata K; Abe K; Hirano F; Tohgo A; Hoshiai H; Noda K
Oncol Rep; 2003; 10(3):593-8. PubMed ID: 12684629
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of concurrent chemoradiation with weekly nedaplatin in patients with squamous cell carcinoma of the uterine cervix.
Yoshinaga K; Niikura H; Ogawa Y; Nemoto K; Nagase S; Takano T; Ito K; Yaegashi N
Gynecol Oncol; 2007 Jan; 104(1):36-40. PubMed ID: 16889822
[TBL] [Abstract][Full Text] [Related]
20. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
